Plain-English translation of NCT06523699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called CYT107, a man-made immune protein, given to multiple myeloma patients after they receive a stem cell transplant. The study compares patients who receive the standard transplant treatment alone versus those who also receive CYT107 for 4 weeks afterward. Researchers believe this medication may help your immune system recover better and fight off any remaining cancer cells.
After a stem cell transplant, patients' immune systems are weakened and take time to rebuild, which can allow cancer to return and infections to develop. This trial is testing whether the medication can speed up immune recovery and improve long-term outcomes after transplant.
You likely qualify if…
You likely don't qualify if…
All participants will receive the standard stem cell transplant treatment using chemotherapy conditioning. After transplant, about half the participants will randomly receive the new medication CYT107 as 5 injections under the skin over 4 weeks (2 doses the first week, then 1 dose per week for 3 more weeks), while the other half will receive standard care alone. You will have regular clinic visits and blood tests to monitor your recovery, immune function, and how well the cancer responds to treatment.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States